title: Evaluation of bioreductive activation of anticancer drugs idarubicin and mitomycin C by NADH-cytochrome b5 reductase and cytochrome P450 2B4.
abstract: This study attempted to investigate the ability of microsomal NADH-cytochrome b5 reductase and cytochrome P450 2B4 to reductively activate idarubicin and mitomycin C.        In vitro plasmid DNA damage experiments and assays using purified hepatic enzymes were employed to examine their respective roles in the metabolic activation of anticancer drugs.        Mitomycin C was found to be not a good substrate for microsomal b5 reductase unlike P450 reductase. It produced low amounts of strand breaks in DNA when incubated with b5 reductase and its one-electron reduction by purified enzyme was found as negligible. Our findings revealed that P450 reductase-mediated metabolism of idarubicin resulted in a large increase in single-strand DNA breaks, whereas, b5 reductase neither catalyzed the reduction of idarubicin nor mediated the formation of DNA damage in the presence of idarubicin. The reconstitution studies, on the other hand, have identified rabbit liver CYP2B4 isozyme as being a potential candidate enzyme for reductive bioactivation of idarubicin and mitomycin C.        Thus, the present novel findings strongly suggest that while b5 reductase could not play a key role in the cytotoxic and/or antitumor effects of idarubicin and mitomycin C, CYP2B4 could potentiate their activity in combination with P450 reductase.
authors.affiliation: Biochemistry Graduate Programme and Department of Biological Sciences, Middle East Technical University, Ankara, Turkey.
authors.forename: Haydar
authors.initials: H
authors.lastname: Celik
authors.forename: Emel
authors.initials: E
authors.lastname: Arinç
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001189:Aryl Hydrocarbon Hydroxylases / Q000378:metabolism*; D002417:Cattle; D000072467:Cytochrome P450 Family 2; D042966:Cytochrome-B(5) Reductase / Q000378:metabolism*; D053960:DNA Breaks / Q000187:drug effects; D015255:Idarubicin / Q000494:pharmacology*; D008862:Microsomes, Liver / Q000187:drug effects / Q000201:enzymology; D016685:Mitomycin / Q000494:pharmacology*; D009243:NAD / Q000378:metabolism; D009249:NADP / Q000378:metabolism; D010084:Oxidation-Reduction / Q000187:drug effects; D010957:Plasmids / Q000378:metabolism; D011817:Rabbits
chemical_list: D000970:Antineoplastic Agents; D009243:NAD; D016685:Mitomycin; D009249:NADP; D001189:Aryl Hydrocarbon Hydroxylases; D000072467:Cytochrome P450 Family 2; C465241:cytochrome P-450 CYP2B4 (rabbit); D042966:Cytochrome-B(5) Reductase; D015255:Idarubicin